Visterra closes $26m Series A, to take flu antibody into clinic
This article was originally published in Scrip
Fresh off a drug discovery deal with Pfizer, infectious disease-focused Visterra has raised $13 million to complete a $26 million Series A venture financing round to advance VIS410, a broad spectrum monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza, and potentially another drug candidate into clinical development.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.